Kyntra Bio
KYNB
34 hedge funds and large institutions have $10.1M invested in Kyntra Bio in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 4 closing their positions.
400% more call options, than puts
Call options by funds: $2.11M | Put options by funds: $422K
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
6% more funds holding
Funds holding: 32 → 34 (+2)
0.45% more ownership
Funds ownership: 28% → 28.45% (+0.45%)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
27% less capital invested
Capital invested by funds: $13.9M → $10.1M (-$3.77M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$223K |
| 2 |
AC
Armistice Capital
New York
|
+$215K |
| 3 |
Two Sigma Investments
New York
|
+$205K |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
+$188K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$126K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$721K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$390K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$66.1K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$45.9K |
| 5 |
Squarepoint
New York
|
-$40.9K |
KYNB Hedge Fund Activity: Q4 2025 in Review
34 of the 8,264 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q4 2025, worth a combined $10.1M — down 27% from $13.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new KYNB positions and 4 closed out — a net gain of 2 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $223K. The largest seller was Primecap Management, exiting entirely with an estimated $721K sold.
- 34 institutional investors held Kyntra Bio (KYNB) as of Q4 2025, up from 32 in Q3 2025.
- Funds reported $10.1M of Kyntra Bio stock for Q4 2025, down 27% quarter-over-quarter.
- 6 funds opened new Kyntra Bio positions in Q4 2025 and 4 closed out, a net change of +2 holders.
- The largest Kyntra Bio buyer in Q4 2025 was Two Sigma Advisers, an estimated $223K added.
- The largest Kyntra Bio seller in Q4 2025 was Primecap Management, an estimated $721K sold.
Based on aggregated 13F filings for Q4 2025.